Glaxo and other are desperate
https://www.bloomberg.com/apps/news?pid=20601087&sid=aUb73rPBTkaE
His comments about acquiring new treatments and building anorphan-drug business underscore the pressure facing drugmakers,which aren’t developing products fast enough to offset therevenue they’re losing to lower-priced copies. Drugs generating$187 billion in sales are threatened by generics between 2011and 2014 as patents expire, according to EvaluatePharma, aLondon-based consulting firm.
Humm... E.coli and Shigamabs = orphan drug status. 4601 GBM also orphan drug status.
Hope he is talking about us.
Slaoui did say that Glaxo will announce next month a moveinto drugs for rare diseases. He declined to name diseases thatthe company will target. So-called orphan medicines currentlyexist to treat illnesses including the genetic disorder Gaucherdisease.
Hummm... I remember posting months ago about How Pharmas are interested in orphan drugs...